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In a world where food availability is intermittent, survival 
requires the capacity to store ingested calories in excess 
of immediate requirements o that energy may be re- 
leased at a later point upon demand. To orchestrate these 
processes of energy storage and release, highly inte- 
grated systems have evolved, and these operate on sev- 
eral physiological levels. As for many complex physiologic 
systems, the brain provides an essential coordinating role. 
Most important are the hypothalamic enters (see Figure 
1) that coordinate nergy homeostasis through regulation 
of food intake (hunger and satiety), energy expenditure 
(thermogenesis), and the secretion of hormones (espe- 
cially insulin) that regulate substrate interconversion, stor- 
age, and mobilization. But where does the energy storage 
take place? Enter the adipocyte, and along with it obesity, 
a remarkably prevalent disorder that is defined as a state 
of pathologically increased adipose cell mass. Is the adipo- 
cyte an innocent bystander, or does it play an active role 
in the regulation of energy homeostasis and body compo- 
sition? Although adipose cell enlargement and eventual 
hypertrophy are the defining features of obesity, the adipo- 
cyte has been viewed as a largely passive participant in 
the disease process, accumulating or losing lipid stores 
in response to alterations in substrates and regulatory sig- 
nals produced at distant sites. As a cell type, therefore, 
the adipocyte has received a great deal of attention only 
recently, and obesity, the dominant disease affecting adi- 
pocyte function, has lacked major breakthroughs in the 
realm of molecular pathogenesis. Indeed, much of the im- 
portant research in obesity hastaken place in departments 
of psychology and psychiatry. Recent advances in the 
area of adipocyte development and evidence that the adi- 
pocyte can function as an endocrine cell have promised 
to change this situation radically and permanently, and 
these are the subject of this minireview. 
The Black Box of Energy Balance 
Viewed broadly, obesity is a disorder of energy balance, 
occurring when energy intake chronically exceeds energy 
expenditure. It is now clear that in normal physiology, 
these two components of the energy balance equation 
(i.e., energy intake and expenditure) are linked, not inde- 
pendent, variables. When food intake increases, so does 
energy expenditure, and vice versa. Teleologically, this 
could be viewed as a mechanism to conserve calories 
when food deprived and to prevent obesity when excess 
food is ingested. Much has been learned about the mecha- 
nism by which chronic overfeeding increases energy ex- 
penditure beyond the energetic osts of digestion, absorp- 
tion, metabolic interconversions, and carrying around the 
extra weight. This adaptive thermogenesis involves the 
activation of the sympathetic nervous system, and, at least 
in rodents, subsequent stimulation of heat production in 
brown adipose tissue (BAT) (Himms-Hagen, 1989). BAT 
is the physiologic opposite of white adipose tissue, being 
designed to burn, not store, energy, and to release the 
energy as heat. BAT accomplishes this through a unique 
mitochondrial protein (thermogenin, or uncoupling pro- 
tein) that uncouples fuel oxidation from ATP generation 
by collapsing the hydrogen ion gradient across the inner 
mitochondrial membrane (Nicholls and Locke, 1984). The 
recent demonstration that animals made deficient in BAT 
through a transgenic toxigene (Lowell et al., 1993) devel- 
oped not only efficient metabolism and obesity but hyper- 
phagia as well, strongly suggested that food intake and 
energy expenditure are linked through BAT, via an as-yet- 
unknown signaling mechanism. The existence of such a 
physiologic link between energy intake and expenditure 
has also been suggested by several of the genetic models 
of spontaneous obesity in rodents that have been studied 
for the past 30 years (Bray and York, 1979; Friedman and 
Leibel, 1992). In these single-gene autosomal recessive 
disorders (ob/ob, db/db), severe obesity is always accom- 
panied by both hyperphagia nd diminished energy ex- 
penditure, the latter associated with BAT dysfunction due 
to inadequate stimulation by the sympathetic nervous sys- 
tem. The molecular link between excessive food intake 
and decreased energy expenditure, although fundamen- 
tal, has remained obscure. Since closely apposed hypo- 
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Figure 1. Major Components of the Body Weight Regulatory System 
The brain, working primarily through ypothalamic centers, influences 
body weight through effects on hunger and satiety, integration ofsecre- 
tion of key hormones uch as insulin, and energy expenditure, includ- 
ing actions to regulate BAT via sympathetic nervous ystem (SNS) 
innervation. These combine to determine the the state of energy stor- 
age in adipose cells. The adipocyte plays an active role through the 
regulated secretion of a number of secreted products. These include 
the product of the ob gene, which is predicted to regulate hypothalamic 
function through feedback that may be direct or indirect. The mecha- 
nism coupling expression of the ob product o fat cell stores is un- 
known. Other secreted products, such as TNFa, may contribute o the 
morbid complications ofobesity through overexpression i  enlarged 
adipocytes. 
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thalamic centers can regulate these two processes, it had 
been surmised that primary defects in the hypothalamus 
may underlie these obesities. It is now apparent, however, 
that the adipocyte itself may be a central player in the 
signaling loop. This concept fits well with the gathering 
evidence that the adipocyte is not quite as passive as it 
once appeared. 
The Adipocyte Acquires New Roles 
The established role for the adipocyte is to serve as the 
site of triglyceride storage or free fatty acid release in re- 
sponse to changing energy needs. However, the notion 
that the adipocyte might also function as a more active 
component of energy homeostasis has been around for 
many years. It was proposed that the adipocyte might be 
capable of sensing excessive energy stores and, in re- 
sponse, provide a signal (the "adipostat") that would limit 
food intake, thereby facilitating maintenance of a desired 
"set point" of body fat (Kennedy, 1953; Mrosovsky, 1986). 
As the discovery of a candidate effector for signaling from 
the adipocyte failed to materialize, the interest in this hy- 
pothesis waned. 
In recent years, the hypothesis has been reawakened, 
alongside observations that the adipocyte was capable of 
producing and secreting molecules with regulatory poten- 
tial. Adipsin is a serine protease secreted by adipocytes 
that was discovered as a differentiation-dependent mRNA 
in a cultured adipocyte cell line (Cook et al., 1985). The 
observation that expression of this molecule was mas- 
sively reduced in many models of rodent obesity and that 
its circulating levels were similarly reduced raised a hope 
that this could be the long-sought adipostatic signal (Flier 
et al., 1987). Further studies revealed that adipsin was a 
member of the alternative complement pathway (comple- 
ment factor D) (Rosen et al., 1989) and that its repletion 
failed to alter the physiology of obesity. Obese humans, 
unlike rodents, are not adipsin/D deficient. Although the 
consequences of regulated expression of this molecule 
in adipocytes remain unclear, recent evidence that adip- 
sin/D might have actions to generate complement pep- 
tideswith the ability to stimulate triglyceride acylation may 
be a clue (Baldo et al., 1993). Subsequently, the adipocyte 
became known as a site for dysregulated expression and 
secretion of an increasing number of interesting mole- 
cules, including peptides such as angiotensinogen (Fred- 
erich et al., 1992) that are produced in other sites as part 
of regulatory systems unrelated to fuel homeostasis. 
A provocative example of such a molecule is tumor ne- 
crosis factor ~ (TNF~). TNF~ is a cytokine that is ex- 
pressed in macrophages and a number of other cells; its 
expression is induced by bacterial lipopolysaccharide. 
The discovery that this molecule is also expressed by adi- 
pocytes was an outgrowth of studies on the regulation of 
complement proteins in adipocytes and was made all the 
more remarkable by the surprising observation that adipo- 
cytes of obese animals and humans have markedly in- 
creased TNF~ expression (Hotamisligil et al., 1993, 1994). 
Recent studies reveal that the consequences of TN F~ dys- 
regulation are clearer than underexpression of adipsin has 
so far proved to be. Thus, it is strongly linked to one of 
the most deleterious consequences of the obese state: 
insulin resistance. Considerable attention is now being 
focused on the mechanism by which TNF~ induces resis- 
tance in the cascade of insulin signal transduction, the 
mechanism for tissue-specific overexpression in the obese 
adipocyte, and the possibility that interference with this 
pathway could be a new therapeutic approach to abrogat- 
ing insulin resistance and thereby obesity-linked iabetes. 
Whether TNF~ expression in obesity participates in a 
physiologic loop, perhaps related to limitation of obesity 
at the expense of insulin resistance, may require metabolic 
studies of mice with genetic alterations in the TNF~ system. 
The ob Gene 
The autosomal recessive mutation causing the syndrome 
of obesity in mice, known as ob/ob, was discovered in the 
mouse colony of The Jackson Laboratory in 1950 and was 
mapped to chromosome 6. These mice develop severe 
Obesity from a very early age and display both marked 
hyperphagia nd diminished energy expenditure. The lat- 
ter is made evident by the development of obesity in ob/ 
ob mice fed identical calories with lean littermates and by 
their poor tolerance for exposure to environmental cold, 
which requires regulated increases in energy expenditure. 
Through a positional cloning approach, the identification 
of the ob gene was very recently reported (Zhang et al., 
1994), and the preliminary indication is that this gene pro- 
vides a major new insight into the regulatory role of the 
fat cell in energy balance. 
The ob gene encodes a 4.5 kb mRNA that is apparently 
expressed solely in adipose tissue (presumably adipo- 
cytes). The predicted protein product is a 167 amino acid 
protein with no homology to proteins in the data bases. 
The presence of a signal sequence suggests that it is a 
secreted protein. Of two coisogenic strains of ob mice, 
one (the original) has a nonsense mutation, and the other 
has no mRNA and a presumed deletion affecting the pro- 
moter region. This genetic evidence is powerful and will 
hopefully be rapidly followed by a demonstration that the 
ob protein exists in plasma and is absent in the ob/ob mice 
and that repletion of the active protein will reverse the 
disease. If so, what will be the major questions to be an- 
swered? 
A fundamental question is the precise mechanism by 
which the putative ob hormone acts to influence appetite, 
energy expenditure, and other systems (such as reproduc- 
tion and growth) that are known to be abnormal in mutant 
ob/ob mice. The most likely may be an action of this periph- 
erally produced protein/hormone to influence hypothala- 
mic function. One problem confronting such a hypothesis 
is the presence of the blood-brain barrier. However, a 
number of peripheral peptides, including angiotensin II, 
can rapidly affect the hypothalamus through nerve cells 
in the region of the circumventricular organs that lie out- 
side the blood-brain barrier (Tanaka and Nomura, 1993). 
Alternatively, as seems to be the case for the gut peptide 
CCK, signals could be brought to the hypothalamus via 
stimulation of vagal afferent axons. Either ob itself or a 
molecule in the periphery whose levels are influenced by 
ob could bring this signal to the brain. It will be interesting 
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to determine how ob relates to other peptides in the periph- 
eral circulation already viewed as having the capacity to 
regulate appetite, such as CCK and insulin itself. 
In any case, a major focus of investigation will turn to 
the hypothalamus and to attempts to identify a molecular 
and anatomical target(s) for the action of the ob protein 
(or its downstream mediator) in the brain. It is interesting 
to note that, based on parabiosis studies performed at 
The Jackson Laboratory in the 1950s, the ob gene was 
hypothesized to encode a satiety molecule and the db 
gene to encode a required component of the response to 
this satiety molecule (Coleman, 1973). Whether this hy- 
pothesis will be validated and whether such validation will 
first result from posi{ional cloning of the db gene or from 
studies of the ob protein remain to be determined. In any 
event, both for basic biology and for the anticipated evel- 
opment of new anti-obesity drugs, the focus on the pre- 
sumed hypothalamic targets will be intense. One clue 
might be derived from recent observations with the yellow 
agouti mouse. These mice have an autosomal dominant 
syndrome of obesity due to a genetic lesion that causes 
widespread ectopic expression of the agouti protein, a 
protein normally restricted to the skin (Bultman et al., 
1992). The observation that agouti can antagonize the me- 
lanocyte-stimulating hormone a-MSH (Lu et al., 1994)is 
interesting, since receptors for this neuropeptide are ex- 
pressed in the hypothalamus. 
A second issue involves the nature of regulated ob ex- 
pression in the adipose cell and the role that the protein 
normally plays in short- or long-term regulation of body 
fat content. By what mechanism might the level of ob re- 
flect the state of adipose stores? Is the level of ob expres- 
sion regulated by a critical intracellular metabolite, by one 
or more hormones (e.g., insulin) that parallel the state of 
adipose storage of triglyceride, or by a combination of 
these and other factors? 
Finally, a substantially conserved human homolog of ob 
mRNA has been identified in human fat, and assessing 
the role of the encoded protein in human obesity and in 
obesity-linked iabetes will require additional study. Per- 
haps some rare cases of severe early-onset obesity in 
humans will be due to mutations in the ob gene. It will also 
be critical to determine whether more common varieties of 
human obesity will be associated with altered regulation 
of the ob protein or resistance to its action. 
Whither the Adipocyte? 
With the realization that the adipocyte is a "smart cell," 
possessing (quite likely) the capacity to communicate di- 
rectly or indirectly with the brain, interest in the origin and 
fate of this cell type is certain to be piqued. Fortunately, 
another breakthrough in this area greets us. Spiegelman 
et al. have reported what appears to be the holy grail itself: 
identification of a gene whose protein product may regu- 
late the determination of the adipocyte lineage, as seen 
after forced expression to physiologic levels in fibroblasts 
(Tontonoz et al., 1994a). The gene is expressed exclu- 
sively in adipocytes and encodes a member of the peroxi- 
some proliferator-activated receptor subfamily of nuclear 
hormone receptor transcription factors, designated PPAR¥2 
(Tontonoz et al., 1994b). Two aspects of the regulatory 
potential of this factor are worthy of emphasis. First, 
PPAR'y2 may operate in concert (and synergistically) with 
a basic-leucine zipper transcription factor, C/EBP~, which, 
although not adipocyte specific, is induced (somewhat 
later) with differentiation and can influence the expression 
of several fat-specific genes and differentiation itself (Sam- 
uelson et al., 1991 ; Umek et al., 1991). Second, and poten- 
tially of even greater importance, is the fact that PPARy2 
is a lipid-activated transcription factor. As such, this sug- 
gests a mechanism whereby lipid metabolism or flux might 
directly regulate the number of adipose cells in tissue, 
perhaps analagous to the ability of cardiac stretch to in- 
duce hypertrophy of that tissue. Whether the activating 
ligand is any free fatty acid or a specific metabolite is a 
key question now amenable to an answer, and this should 
provide a tool that could enable discovery of potent new 
drugs, capable of regulating adipose cell number in vivo. 
Would such a drug be valuable if developed? In a sense, 
this brings us back to our initial question regarding the 
role of the adipocyte in the genesis of obesity. If the adipo- 
cyte was merely a repository for stored calories, interfer- 
ence with the process of adipogenesis in the face of excess 
food intake might limit obesity (since the maximal size of 
an adipocyte is finite), but produce adverse consequences 
through uncontrolled exposure to lipid at other tissue sites. 
On the other hand, given the fact that the adipocyte plays 
a key role in the regulation of food intake and energy ex- 
penditure, restricted expansion of adipose cell number 
might have favorable consequences. This was suggested 
many years ago by investigators who argued that "hyper- 
plastic" obesity was more refractory to diet therapy than 
was"hypertroph ic" obesity, in which adipose cells enlarge, 
but their number is unchanged. 
Conclusion 
It is clear that adipocytes, both brown and white, will re- 
ceive far more attention from the scientific community than 
they once did. These cells are at the center of a key regula- 
tory system for maintenance of energy stores, and hence- 
forth obesity must be viewed as a disorder both of and by 
the adipocyte. From both the basic and applied perspec- 
tives, the next few years will likely be the "fat years" of 
obesity research. 
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